Oversættelse af europæisk patentskrift

(51) Int.Cl.: A 61 K 36/185 (2006.01) A 61 K 31/366 (2006.01) A 61 K 31/7048 (2006.01)
A 61 P 27/02 (2006.01)

(45) Oversættelsen bekendtgjort den: 2017-01-09

(80) Dato for Den Europæiske Patentmyndighedens
bekendtgørelse om meddelelse af patentet: 2016-09-14

(86) Europæisk ansøgning nr.: 12726639.1

(86) Europæisk indleveringsdag: 2012-05-14

(87) Den europæiske ansøgnings publiceringsdag: 2014-04-16

(86) International ansøgning nr.: FR2012000193

(87) Internationalt publikationsnr.: WO2012156600

(30) Prioritet: 2011-05-13 FR 1154172

(84) Designerede stater: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(73) Patentehaver: Biophytis, 14 Avenue de l'Opéra, 75001 Paris, Frankrig
Université Pierre et Marie Curie (Paris 6), 4, Place Jussieu, 75252 Paris, Frankrig

(72) Opfinder: VEILLET, Stanislas, 3 rue du Docteur Maxime Ménard, F-91600 Savigny sur Orge, Frankrig
LAFONT, René, 30 rue Claude Lorrain, F-75016 Paris, Frankrig
FONTAINE, Valérie, 224 rue de Tolbiac, F-75013 Paris, Frankrig
SAHEL, José-Alain, 4 rue Dieulafoy, F-75013 Paris, Frankrig

(74) Fuldmægtig i Danmark: Plougmann Vingtoft A/S, Rued Langgaards Vej 8, 2300 København S, Danmark

(54) Benævnelse: Bixa Orellana-sammensætning til behandling af makulær degeneration

(56) Fremdragne publikationer:
WO-A1-2010/149942
WO-A2-01/85183
TERASHIMA S ET AL.: "Studies on aldose reductase inhibitors from natural products. IV. Constituents and aldose reductase inhibitory effect of Chrysanthemum morifolium, Bixa orellana and Ipomoea batatas."
"Bixitia", website Biophytis, 8 november 2011 (2011-11-08), XP002663846, Extrait de l'Internet:

Fortsættes...
Bixa orellana composition for the treatment of macular degeneration

The invention relates to the use of compounds and a composition for preventing certain diseases of the retina.

The invention aims to improve the vision of diseased people, or at least stabilize the development of these diseases.

Age-related macular degeneration, or AMD, is a chronic degenerative retinal disease, progressive and disabling, affecting the elderly and whose origin is multifactorial (Bellmann and Sahel, 2007). In France, it is the major cause of visual impairment above 50 years and the number of people affected is estimated at one million. A disease with genetic predisposition (Fajnkuchen and Cohen, 2008), it is responsible for a growing number of cases of bad vision, proportional to the increase in life expectancy. This disease affects a small part of the retina, the macula, an area that used to fix objects, to read, recognize faces and discern colors. AMD is most likely polygenic with the intervention of risk factors such as prolonged exposure to light, high blood pressure, hypercholesterolemia and smoking. There are two types of AMD, the dry or atrophic form which represents 80 % of cases, and the wet form. Only the latter, which is characterized by the appearance of new blood vessels behind the retina, can presently benefit from treatments.

The pathophysiological mechanisms of AMD are still poorly known, but the involvement of processes of intoxication leading to the death of the retinal pigmented epithelium (RPE) cells has been established over recent years. Indeed, during aging, these cells may exhibit dysfunctions related to lysosomal accumulation of protein-lipid complexes called lipofuscin granules. These granules are progressively formed by the accumulation of undegraded proteins and lipids originating from the phagocytosis by the RPE of the outer segments of photoreceptors (Finnemann et al., 2002). Lipofuscin also includes cytotoxic derivatives of visual cycle pigments, such as A2E, which is formed by a combination of two molecules of trans-retinal with an ethanolamine molecule. Under the effect of blue light, A2E is oxidized and induces protein, lipid and DNA oxidation, causing a significant oxidative stress in the RPE cells during aging (Kim et al. 2006). Attempts at prevention or treatment of dry AMD are based on nutritional supplementation with substances that reduce the accumulation and / or adverse effects of A2E (Dubernard et al., 2006; Souied et al. 2007; Dutot et al., 2008; Lecerf, 2009; Cohen et al, 2010; Lecerf and Desmettre, 2010).
Given the very probable role of this mechanism in the development of AMD, the inventors used an in vitro cellular model of induced phototoxicity by the association of a treatment with A2E and illumination by blue light on RPE primary cell cultures wherein cell survival was measured. This model was developed by the Institute of Vision and allows for screening molecules aimed to discover new candidates for the treatment of dry AMD. This original model is closer to the "physiological" situation than cell lines commonly used in other laboratories (Dunn et al., 1996), because the cells used already contain protective substances originating from the animal diet and thus are not in a situation of "deficiency", and their disturbance is induced by the addition of A2E.

The invention thus provides an opportunity to find an alternative treatment to already existing ones.

Specifically, the inventors have discovered that the prior incubation of cells with certain molecules greatly reduces the cell death caused by illumination with blue light of RPE cells pretreated with A2E.

According to the invention, these molecules are present in a urucum extract, or are derivatives of gallic acid or compounds of the family of anthocyanidins.

One aspect of the invention therefore relates to a composition comprising an extract of urucum seeds for photoprotection cells of retinal pigment epithelium in a mammal.

The urucum or achiote, or *Bixa orellana* is a tree or shrub of tropical America. It produces red fruit filled with seeds thorns.

In the context of the invention, the term "seed extract of *Bixa orellana" is an extract prepared from the outer coat of the seeds, that is to say, the waxy substance covering the seeds of *Bixa orellana*. This waxy substance is known to be rich in bixin and carotenoids, as well as its use as a food coloring agent.

It is known from WO 01/85183 a composition for the prevention and treatment of eye disorders, said compositon may include an extract of *Bixa orellana* as an inhibitor of aldose reductase.

This extract comprises gallic acid and / or pyrogallol, thus it is probably a leaf extract of *Bixa orellana*, as described by Terashima et al. [Chem. Pharm. Bull. 39 (12), 3346-3347 (1991)], which actually shows its activity as an inhibitor of aldose reductase.

In addition, WO 01/85183 shows the inhibition of aldose reductase as part of a mechanism to protect against cataracts and diabetic retinopathy.
WO 01/85183 does not therefore show the effectiveness of an extract from seeds of *Bixa orellana* for photoprotection of RPE cells.

According to one embodiment of the present invention, the composition of seeds of *Bixa orellana* is for the treatment of macular degeneration related to age (AMD) in the mammal.

According to another embodiment of the invention, the composition is intended to treat Stargardt’s disease and/or retinitis pigmentosa. Stargardt’s disease or Stargardt’s syndrome is a hereditary disease, involving a bilateral decrease in visual acuity due to atrophy of the macula.

According to another embodiment of the invention, the composition is intended to prevent damage to the retina may be caused by exposure to blue radiation. Blue rays by means of the radiation corresponding to the blue part of the spectrum of visible light, or wavelengths comprised between 435 and 490 nm.

According to one embodiment of the invention, the composition further comprises a derivative of gallic acid and/or a compound of the anthocyanidin family.

The gallic acid derivative can be ellagic acid, either pure or provided as a pomegranate extract. Indeed, pomegranate contains ellagic acid in large quantities (Panichayupakarananta et al., 2010).

The compound of the anthocyanidin family may be cyanidin, either purie or provided in the form of an Acai extract. This plant does indeed contain cyanidin glycosides. Cyanidin may also be provided in the form of an extract of Hibiscus.

The composition of *Bixa orellana* seeds can be used as a food, a dietary supplement or a medicament.

Dietary supplement means a product containing said compound or extract or enriched in said compound extracted intended to supplement the diet by providing nutrients beneficial to health as defined by the European Directive 2002/46/EC. For example, a food supplement can be a capsule or tablet to swallow or a powder or small ampulla to be mixed with food and providing beneficial effects on the retina.

A drug means a product containing a precise dose of said compound or said extract as defined by European Directive 65/65/CE ie any substance or composition presented as having properties for treating or preventing the disease in human beings or animal. For example, the drug containing the compound at therapeutic doses may be administered orally in capsule or tablet form or injected intravitreally or administered by any other way to give beneficial effects on the retina.
Another aspect of the invention relates to a composition comprising a
derivative of gallic acid and/or a compound of the anthocyanidin family, for
photoprotection of the retinal pigmentary epithelium in the mammal.

The gallic acid derivative is preferably ellagic acid, especially purified form or
made of an extract of pomegranate. The compound of the anthocyanidin family is
preferably cyanidin, either purie or provided in the form of an extract of Acai or
Hibiscus.

The applications of this alternative composition are the same as those of the
previously mentioned composition comprising an extract of Bixa orellana seeds. As
well as the latter, the other compositions may be used as a food, a dietary
supplement or a medicament.

The invention will be better understood upon reading the following description
and examining the accompanying figures. These are for information only and not
limiting of the invention.

Figure 1 illustrates the effect of an extract urucum of bixin and norbixin on the
protection of the EPR tested for phototoxicity.

Figure 2 illustrates the effect of chlorogenic acid, rutin and of ellagic acid on
the protection of the EPR tested for phototoxicity.

Figure 3 illustrates the effect of cyanidin, cyanidin-3-glucoside or delphinidin-
3- sambubioside and 20-hydroxyecdysone on the protection of the EPR tested for
phototoxicity.

Embodiments of the invention

I. Preparing an extract of Bixa orellana (extract A)

Extract A is made by stirring the seeds urucum in absolute ethanol (3 L per kg
of seeds) for 16 hours. The agitation in alcohol has the effect of detaching the waxy
film on the surface lying seeds.

A suspension is obtained. It is sieved to remove urucum seeds. This
suspension is then reduced to 1/8th then decanted. A heavy suspension is formed.

The lipid-rich supernatant is eliminated. Maltodextrin is added to the solid
deposit and the mixture is spray dried.

The extract contains 16% by weight of bixin. In the following examples, the
concentration of the extract is expressed in bixin equivalents.
Extract A is also rich in carotenoids. It also contains other terpenic compounds such as geranylgeraniol and tocotrienols (90 % δ and 10 % β) and several flavonoids.

The extract has the following features for 100 g (Table 1):

<table>
<thead>
<tr>
<th>Energetic value</th>
<th>319.04 Kcal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbohydrates (by difference)</td>
<td>38.10 g</td>
</tr>
<tr>
<td>Bixin</td>
<td>16 g</td>
</tr>
<tr>
<td>Protein</td>
<td>7.7 g</td>
</tr>
<tr>
<td>Fat (by hydrolysis)</td>
<td>1.6 g</td>
</tr>
<tr>
<td>Total fibers</td>
<td>27.9 g</td>
</tr>
<tr>
<td>Sodium</td>
<td>8.2 mg</td>
</tr>
<tr>
<td>Humidity</td>
<td>6%</td>
</tr>
<tr>
<td>Minerals</td>
<td>4.3 %</td>
</tr>
</tbody>
</table>

According to one embodiment of the invention, the extract A can be subjected to saponification, so as to turn all or part of bixin to norbixin.

II. Activity assays

The inventors have tested 15 natural substances and extract A on a RPE cellular model of phototoxicity described below (Table 2).

<table>
<thead>
<tr>
<th>Type</th>
<th>Compound name</th>
<th>Source (example)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive controls</td>
<td>Lutein</td>
<td>Spinach</td>
</tr>
<tr>
<td></td>
<td>Zeaxanthin</td>
<td>Maize</td>
</tr>
<tr>
<td></td>
<td>Resveratrol</td>
<td>Grape</td>
</tr>
<tr>
<td>Carotenoids</td>
<td>Bixin</td>
<td>Urucum</td>
</tr>
<tr>
<td></td>
<td>Norbixin</td>
<td>&quot; &quot;</td>
</tr>
<tr>
<td>Phenolic acids</td>
<td>Chlorogenic acid</td>
<td>Mate</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>------</td>
</tr>
<tr>
<td>Flavone</td>
<td>Orientin</td>
<td>Açaí</td>
</tr>
<tr>
<td>Flavonol</td>
<td>Rutin</td>
<td>Buckwheat</td>
</tr>
<tr>
<td>Flavanone</td>
<td>Naringenin</td>
<td>Lemon</td>
</tr>
<tr>
<td>Benzopyrane</td>
<td>Ellagic acid</td>
<td>Pomegranate</td>
</tr>
<tr>
<td>Anthocyanins</td>
<td>Cyanidin 3-glucoside</td>
<td>Açaí</td>
</tr>
<tr>
<td></td>
<td>Delphinidin 3-sambubioside</td>
<td>Hibiscus</td>
</tr>
<tr>
<td>Anthocyanidins</td>
<td>Cyanidin</td>
<td>Açaí*</td>
</tr>
<tr>
<td>Steroids</td>
<td>20-Hydroxyecdyson</td>
<td>Quinoa</td>
</tr>
</tbody>
</table>

* The cyanidin is prepared after acid hydrolysis of its glycosylated forms

To test the photoprotective effect of the test substances, the inventors used a cellular model of induced phototoxicity by treatment with A2E followed by illumination with blue radiation. This model was produced from primary cultures of adult porcine RPE cells. Cell survival was determined by the ratio between the number of living cells and the total number of cells (alive + dead, respectively quantified using specific staining). Image acquisition was performed using a fluorescence microscope controlled by Metamorph software and quantifications were made by processing images acquired by a program dedicated quantification. The experiments were performed in 96-well microplates in quadruplicate and the experiment was repeated at least four times. Cells were treated for 48 hours with these compounds, the last 24 hours in the presence of A2E before induction of phototoxicity. Three concentrations (0.1, 1 and 10 μM) were tested for each compound. Some compounds were further tested at 20 μM to achieve a range of concentrations.

III. Results

The results, presented as averages and standard deviations are expressed as percentage of survival compared to the control without A2E.

The experiments did not show a protective effect of 15 compounds or extract A at concentrations of 0.1 and 1 μM (data not shown for lutein, zeaxanthin, resveratrol, crocetin, naringenin and orientin, and results shown for urucum extract A, cyanidin and ellagic acid in figures 1-3).
In a series of tests (n = 5), extract A allowed a significant protection, with cell survival for 20 μM of the order of 93 % of the control without A2E, to be compared with that of control + A2E, which is only 45 % (Figure 1).

Among the 15 compounds tested at 10 μM, two provide a cellular protection against phototoxicity.

Notably, 10 μM cyanidin provides a protection in the order of 87% survival compared to the control without A2E. At 20 μM, the same compound provides almost complete protection (Figure 2).

Ellagic acid also provides protection in the order of 68% compared to the control without A2E. At 20 μM, this compound provides protection similar to that measured at 10 μM, but with a better reproducibility (Figure 3).

Photoprotective effects expected for lutein, zeaxanthin and resveratrol ("positive controls") were not observed with these experimental conditions.
References


ABSTRACT

Composition of *Bixa orellana* for the treatment of macular degeneration

The invention relates to a composition comprising an extract of seeds of *Bixa orellana* for the photoprotection of the retinal pigment epithelium in mammals.

The invention relates more particularly to the use of such a composition for the treatment of macular degeneration related to age (AMD) in mammals.
Patentkrav

1. Sammensætning omfattende en ekstrakt af frø af Bixa Orellana til fotobeskyttelse af cellerne i det retinale pigmentepitel hos et pattedyr.

2. Sammensætning ifølge krav 1, til anvendelse i behandlingen af aldersrelateret maculadegeneration (AMD) hos et pattedyr.

3. Sammensætning ifølge krav 1, til anvendelse i behandlingen af Stargardts syndrom og/eller retinitis pigmentosa.

4. Sammensætning ifølge krav 1, til forebyggelse af beskadigelse af nethinden, som kunne være forårsaget af udsættelse for blåt lys med en bølgelængde på mellem 435 og 490 nm.

5. Sammensætning ifølge et af kravene 1 til 4, omfattende en bærer, som er acceptabel til at blive indtaget eller injiceret i øjet eller injiceret i blodet.


7. Sammensætning ifølge et af kravene 1 til 6, yderligere omfattende et galsusyrederivat og/eller en forbindelse af familien af anthocyanidiner.

8. Sammensætning ifølge krav 7, kendetegnet ved at galsusyrederivatet er ellaginsyre.

9. Sammensætning ifølge et af kravene 7 eller 8, kendetegnet ved at forbindelsen fra familien af anthocyanidiner er cyanidin.